Astellas
Otsuka to take over Astellas’ Cefixime business
June 7, 2019Medical Communications APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma
Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime. The agreement gives Otsuka the right to sell Cefixime and …
Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS
May 7, 2019Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma
Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …
Top Ten most popular articles on Pharmafile.com this week!
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …
NICE turns down Astellas’ Xtandi in prostate cancer
April 8, 2019Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer
February 18, 2019Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer
Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …
Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia
November 29, 2018Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia
Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …
Astellas’ chronic kidney drug shows superiority at Phase 3
September 20, 2018Research and Development Astellas, chronic kidney disease, pharma, roxadustat
Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …
Astellas acquires gene therapy group Quethera in £85 million deal
August 13, 2018Sales and Marketing Astellas, Japan, gene therapy, ocular, quethera, vision
The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million. …
FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer
July 16, 2018Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …
Top Ten most popular articles on Pharmafile.com this week
May 25, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Gielad, Novartis, brexit, obesity, pharma, top ten
It’s a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an …
Astellas begins major restructure, as 600 jobs slashed
May 24, 2018Medical Communications Astellas, biotech, drugs, pharma, pharmaceutical
Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking …
Seattle Genetics gain breakthrough therapy designation
March 26, 2018Manufacturing and Production, Sales and Marketing Astellas, Seattle Genetics, biotech, drugs, pharma, pharmaceutical
Seattle Genetics and Astellas have confirmed that the drug candidate they are co-developing, enfortumab, has been given FDA breakthrough therapy …
Astellas scoops up Universal Cells for $102.5m
February 15, 2018Sales and Marketing Astellas, Universal Cells, biotech, drugs, pharma, pharmaceutical
Astellas Pharma had only signed an exclusive licensing deal with Universal Cells back in October for the co-development of a …
Astellas confirms Kenji Yasukawa as new President and CEO
February 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, appointment
Japanese pharmaceutical firm Astellas has announced that its Board of Directors has approved the selection of current Chief Strategy Officer …
Pfizer receives prostate cancer drug boost with trial results
September 15, 2017Medical Communications, Research and Development Astellas, Pfizer, Xtandi, biotech, drugs, pharma, pharmaceutical
Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing …
Latest content
FibroFind appoints Lee Borthwick as CEO
